Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis-Reference-Cited by-同舟云学术

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis

Published:2019-11-25 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Piechotta Vanessa¹,Jakob Tina¹,Langer Peter¹,Monsef Ina¹,Scheid Christof²,Estcourt Lise J³,Ocheni Sunday⁴,Theurich Sebastian⁵,Kuhr Kathrin⁶,Scheckel Benjamin¹⁷,Adams Anne⁶,Skoetz Nicole⁸

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Stem Cell Transplantation Program; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

3. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

4. Department of Haematology & Immunology; University of Nigeria; Enugu Nigeria

5. Department of Medicine III; University Hospital LMU, Ludwig-Maximilians-Universität München; Munich Germany

6. Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

7. Institute of Health Economics and Clinical Epidemiology; University of Cologne, Faculty of Medicine and University Hospital Cologne; Cologne Germany

8. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013487/epdf/full

Reference285 articles.

1. Avet-Loiseau H Hulin C Benboubker L Dimopoulos MA Belch A Reece D Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial Blood 2015 730

2. Bahlis N Corso A Mugge LO Shen ZX Desjardins P Stoppa AM Impact of response in patients (pts) with stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) treated with continuous lenalidomide + low-dose dexamethasone (Rd) in the first trial Clinical Lymphoma, Myeloma and Leukemia 2015 e56

3. Bahlis N Corso A Shen ZX Desjardins P Stoppa AM Assessing the benefit of continuous treatment in the first trial (MM-020): impact of response in patients with transplant-ineligible newly diagnosed multiple myeloma Haematologica 2015 85 6

4. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial;Bahlis;Leukemia,2017

5. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;Benboubker;New England Journal of Medicine,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews;Value in Health Regional Issues;2024-09

2. USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway;Oncogenesis;2024-07-19

3. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant;Cochrane Database of Systematic Reviews;2024-05-02

4. Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analyses;BMC Medicine;2024-03-13

5. Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009–2020;Annals of Hematology;2024-03-09